“…In experimental endotoxaemia, dual endothelin receptor antagonists, including bosentan, have improved haemodynamics with increased cardiac index (Oldner et al 1998, Ishimaru et al 2001, attenuated pulmonary hypertension and reduced lung injury (Wanecek et al 1997), as well as improved regional perfusion in the splanchnic region (Oldner et al 1998). So far, the results with non-selective endothelin receptor antagonism and its effects on perfusion pressure have been contradictory (Gardiner et al 1995, Ruetten et al 1996, Oldner et al 1998, Ishimaru et al 2001, Kuklin et al 2004). The few reports on tezosentan in sepsis and endotoxaemia suggest positive effects on cardiac performance (Chin et al 2002, Kuklin et al 2004, lung injury (Kuklin et al 2004, 2005a, renal function (Chin et al 2002) and hepatic injury (Urbanowicz et al 2004).…”